Merrie Cherry, MD
Child & Adolescent Psychiatry · Lexington, SCNPI 1336287762
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.6%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Neurocrine Biosciences, Inc. accounts for 63.1% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $26,873, more than ten times the $252 reported in 2019. Among child & adolescent psychiatry clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 965 payments — averaging $40.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$25K
- Teva Pharmaceuticals USA, Inc.$2K
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Johnson & Johnson$2K
- Otsuka America Pharmaceutical, Inc.$2K
- plus $5K from 15 others
What the payments were for
- Consulting fees$6,80017%
- Speaking & faculty fees$13,00033%
- Travel & lodging$2,6167%
- Food & beverage$16,75143%
- Education$1610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 134 | $24,822 |
| Teva Pharmaceuticals USA, Inc. | 168 | $2,052 |
| AbbVie(2 entities) | 184 | $2,052 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 91 | $2,029 |
| Johnson & Johnson | 98 | $1,903 |
| Otsuka America Pharmaceutical, Inc. | 71 | $1,658 |
| Alkermes, Inc. | 47 | $1,489 |
| Vanda Pharmaceuticals Inc. | 31 | $631 |
| E.r. Squibb & Sons, L.L.C. | 24 | $583 |
| Indivior Inc. | 34 | $467 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $263 |
| Tris Pharma Inc | 14 | $248 |
| Supernus Pharmaceuticals, Inc. | 10 | $193 |
| Corium, LLC | 11 | $189 |
| Noven Therapeutics, LLC | 9 | $154 |
| Lundbeck LLC | 8 | $142 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $140 |
| Idorsia Pharmaceuticals US Inc | 2 | $131 |
| Axsome Therapeutics, Inc. | 4 | $86 |
| Merck | 4 | $61 |
| Eisai Inc. | 2 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$23,036
- LYBALVI$1,377
- ARISTADA$996
- CAPLYTA$495
- REXULTI$249
- ARISTADA INITIO$249
- VRAYLAR$247
- Fanapt$237
- UZEDY$228
- COBENFY$127
- INVEGA SUSTENNA$125
- QUVIVIQ$125
- UBRELVY$125
- ABILIFY MAINTENA$124
How this compares
$39,328 in reported general payments places this provider in the 95th percentile of 71 child & adolescent psychiatry providers in South Carolina.
See all child & adolescent psychiatry providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 73 | $642,380 |
| Invega TrinzaPaliperidone Palmitate | 19 | $196,321 |
| VraylarCariprazine Hcl | 82 | $124,532 |
| Abilify MaintenaAripiprazole | 39 | $113,266 |
| RexultiBrexpiprazole | 56 | $99,222 |
| CaplytaLumateperone Tosylate | 51 | $93,858 |
| PerserisRisperidone | 29 | $90,191 |
| Invega SustennaPaliperidone Palmitate | 33 | $87,217 |
| AristadaAripiprazole Lauroxil | 19 | $68,205 |
| TrintellixVortioxetine Hydrobromide | 90 | $51,125 |
| BelsomraSuvorexant | 57 | $25,724 |
| Lurasidone Hcl | 92 | $22,163 |
| Paliperidone ErPaliperidone | 96 | $15,388 |
| Aripiprazole | 183 | $11,815 |
| Asenapine Maleate | 55 | $9,456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $24,822 | $642,38073 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $1,903 | $283,53852 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,658 | $212,48895 claims |
| AbbVieVraylar | $2,052 | $124,53282 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,029 | $93,85851 claims |
| Indivior Inc.Perseris | $467 | $90,19129 claims |
| Alkermes, Inc.Aristada | $1,489 | $68,20519 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $263 | $51,12590 claims |
| MerckBelsomra | $61 | $25,72457 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 71 child & adolescent psychiatry providers in South Carolina.
Other child & adolescent psychiatry in Lexington
- Victor EvansLexington$26K
- Don DuboseColumbia$290K
- Mary Theresa LaddCharleston$54K
- David SherbondyGreenville$19K
- Eman SharawyGreenwood$9K
- Elena DlugachGreenville$8K
- Elizabeth JeffordsColumbia$5K
- Vikram ShuklaClover$3K
- Stephanie PriceCharleston$3K
- Adrienne PruittCharleston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.